

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Philip Livingston and Friedhelm Helling  
U.S. Serial No.: 08/477,147 Group Unit: 1645  
Filed : June 7, 1995 Examiner: P. Duffy  
For : GANGLIOSIDE-KLH CONJUGATE VACCINE PLUS QS-21

1185 Avenue of the Americas  
New York, New York 10036  
January 21, 2000

Assistant Commissioner for Patents  
Washington, D.C. 20231

SIR:

AMENDMENT IN RESPONSE TO DECEMBER 21, 1998  
OFFICE ACTION AND SUBMITTED AS A FIRST SUBMISSION

This Amendment is submitted in response to an December 21, 1998 Final Office Action issued by the United States Patent and Trademark Office and as a first submission pursuant to a Communication Requesting Withdrawal of Finality under 37 C.F.R. 1.129(a) of the December 21, 1998 Final Office Action. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

In the claims:

Please amend claims 57, 62-64, 71-72 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material and add new claims 78-101 as follows:

--57. (Amended) A composition comprising a ganglioside conjugated through [the] a ceramide-derived carbon [portion] of the ganglioside to [a] Keyhole Limpet Hemocyanin or a derivative thereof and an adjuvant, the amounts of such conjugated ganglioside and such adjuvant

01/25/2000 STEFERRA 00000063 08477147

01 FC:203  
02 FC:202  
03 FC:228  
04 FC:246

207.00 OP  
39.00 OP  
925.00 OP  
345.00 OP